CD274 and neoplasm: Because interactions between PD‐L1and PD‐1 maintain immune tolerance to normal tissues peripherally, blockade of PD‐L1 and PD‐1 results in the activation of the immune system and often causes immune‐related adverse events (irAEs).6 Previous studies have shown that clinical efficacies of anti‐PD‐1/PD‐L1 therapies were augmented in patients with irAEs, suggesting that anti‐PD‐1/PD‐L1 antibodies are capable of stimulating immune responses against both normal cells and tumor cells.7, 8